Enterprise AI startup Kumo is making the case that the next phase of enterprise AI will be shaped by structured and ...
In 2013, fasiglifam, a promising diabetes drug candidate, was withdrawn from late-stage clinical trials by its developer, following signs of liver damage in the trial participants. Like all drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results